MA47465A - Protéines fixant le bcma, le nkg2d et le cd16 - Google Patents

Protéines fixant le bcma, le nkg2d et le cd16

Info

Publication number: MA47465A
Authority: MA; Morocco
Prior art keywords: nkg2d; proteins binding; binding bcma; bcma; proteins
Prior art date: 2017-02-10

Application number

MA047465A

Other languages

English (en)

Inventor

Gregory P Chang

Ann F Cheung

William Haney

Bradley M Lunde

Bianka Prinz

Original Assignee

Dragonfly Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-02-10

Filing date

2018-02-09

Publication date

2019-12-18

2018-02-09 Application filed by Dragonfly Therapeutics Inc filed Critical Dragonfly Therapeutics Inc

2019-12-18 Publication of MA47465A publication Critical patent/MA47465A/fr

Links

BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 title 1
108010008014 B-Cell Maturation Antigen Proteins 0.000 title 1
102000006942 B-Cell Maturation Antigen Human genes 0.000 title 1
101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 title 1
101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 title 1
101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 title 1
102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 title 1
102100022680 NKG2-D type II integral membrane protein Human genes 0.000 title 1
102000004169 proteins and genes Human genes 0.000 title 1
108090000623 proteins and genes Proteins 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

MA047465A 2017-02-10 2018-02-09 Protéines fixant le bcma, le nkg2d et le cd16 MA47465A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201762457780P	2017-02-10	2017-02-10

Publications (1)

Publication Number	Publication Date
MA47465A true MA47465A (fr)	2019-12-18

Family

ID=63107848

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA047465A MA47465A (fr)	2017-02-10	2018-02-09	Protéines fixant le bcma, le nkg2d et le cd16

Country Status (14)

Country	Link
US (1)	US20190375838A1 (fr)
EP (1)	EP3579876A4 (fr)
JP (2)	JP7257323B2 (fr)
KR (2)	KR20190115469A (fr)
CN (1)	CN110461361A (fr)
AU (1)	AU2018219348A1 (fr)
BR (1)	BR112019016424A2 (fr)
CA (1)	CA3054642A1 (fr)
IL (1)	IL268567A (fr)
MA (1)	MA47465A (fr)
MX (1)	MX2019009566A (fr)
MY (1)	MY205850A (fr)
SG (1)	SG11201907253VA (fr)
WO (1)	WO2018148566A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2945620C (fr) *	2014-04-14	2022-12-06	Cellectis	Recepteurs antigeniques chimeriques specifiques de bcma (cd269), utiles dans l'immunotherapie du cancer
CA3221995C (fr)	2017-02-08	2024-05-28	Dragonfly Therapeutics, Inc.	Proteines de fixation multi-specifiques destinees a l'activation de cellules tueuses naturelles et leurs utilisations therapeutiques pour traiter le cancer
US20190375838A1 (en) *	2017-02-10	2019-12-12	Dragonfly Therapeutics, Inc.	Proteins binding bcma, nkg2d and cd16
SG11201907646YA (en)	2017-02-20	2019-09-27	Dragonfly Therapeutics Inc	Proteins binding her2, nkg2d and cd16
CA3072919A1 (fr) *	2017-08-23	2019-02-28	Dragonfly Therapeutics, Inc.	Proteines de liaison a nkg2d, a cd16 et a un antigene associe a une tumeur
KR20200118824A (ko)	2018-02-08	2020-10-16	드래곤플라이 쎄라퓨틱스, 인크.	자연 살해 세포를 활성화시키는 다중-특이성 결합 단백질을 수반하는 암의 병용 요법
PT3749346T (pt)	2018-02-08	2024-09-05	Dragonfly Therapeutics Inc	Combinações de domínios variáveis de anticorpos dirigidas ao receptor nkg2d
CA3091424A1 (fr)	2018-02-20	2019-08-29	Dragonfly Therapeutics, Inc.	Proteines de liaison multi-specifiques qui se lient a cd33, nkg2d et cd16, et procedes d'utilisation
EA202091977A1 (ru) *	2018-05-28	2021-02-09	Драгонфлай Терапьютикс, Инк.	Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения
CA3108646A1 (fr)	2018-08-08	2020-02-13	Dragonfly Therapeutics, Inc.	Proteines de liaison a nkg2d, a cd16 et a un antigene associe a une tumeur
AU2019318083A1 (en) *	2018-08-08	2021-02-25	Dragonfly Therapeutics, Inc.	Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
EA202091888A1 (ru)	2018-08-08	2020-10-23	Драгонфлай Терапьютикс, Инк.	Вариабельные домены антител, нацеленные на рецептор nkg2d
CA3136088A1 (fr) *	2019-05-20	2020-11-26	Matthew T. Burger	Conjugues anticorps-medicament inhibiteurs de mcl-1 et methodes d'utilisation
MX2022013944A (es)	2020-05-06	2022-11-30	Dragonfly Therapeutics Inc	Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
US12043670B2 (en)	2020-06-05	2024-07-23	Eisai R&D Management Co., Ltd.	Anti-BCMA antibody-drug conjugates and methods of use
CN112029001B (zh) *	2020-09-02	2022-09-06	南京北恒生物科技有限公司	靶向nk激活性受体的嵌合抗原受体
US20230365709A1 (en) *	2020-10-08	2023-11-16	Affimed Gmbh	Trispecific binders
WO2022184845A1 (fr)	2021-03-03	2022-09-09	Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus	Anticorps bispécifiques améliorant les réponses immunitaires à médiation cellulaire
JP2024508894A (ja)	2021-03-03	2024-02-28	ドラゴンフライセラピューティクス，インコーポレイテッド	Ｎｋｇ２ｄ、ｃｄ１６、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
IL307312A (en) *	2021-03-31	2023-11-01	Janssen Biotech Inc	Materials and methods for redirecting immune effector cells
WO2024020577A2 (fr) *	2022-07-22	2024-01-25	Fred Hutchinson Cancer Center	Anticorps contre le sars-cov-2

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2009500346A (ja) *	2005-06-29	2009-01-08	ユニバーシティー・オブ・マイアミ	癌処置用の抗体−免疫細胞リガンド融合タンパク質
CN105837690A (zh) *	2006-06-12	2016-08-10	新兴产品开发西雅图有限公司	具有效应功能的单链多价结合蛋白
PT2235064E (pt) *	2008-01-07	2016-03-01	Amgen Inc	Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
TW201109438A (en) *	2009-07-29	2011-03-16	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
EP2306234A3 (fr) *	2009-10-02	2011-06-22	Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V.	Filtre de repliement optique, agencement de capteur à pixels et dispositif de réception numérique
AU2012235758B2 (en) *	2011-03-25	2015-05-07	IGI Therapeutics SA	Hetero-dimeric immunoglobulins
TWI679212B (zh) *	2011-11-15	2019-12-11	美商安進股份有限公司	針對ｂｃｍａ之e3以及ｃｄ３的結合分子
CN107964042B (zh) *	2012-05-30	2022-04-19	中外制药株式会社	靶组织特异性抗原结合分子
CA2871880A1 (fr) *	2012-06-27	2014-01-03	F. Hoffmann-La Roche Ag	Methode de selection et de production d'entites de ciblage personnalisees fortement selectives et multi-specifiques renfermant au moins deux entites de liaison differentes et leurs utilisations
PL2953972T3 (pl) *	2013-02-05	2021-03-08	Engmab Sàrl	Metoda wyboru przeciwciał przeciwko bcma
US10156574B2 (en) *	2013-04-29	2018-12-18	Adimab, Llc	Polyspecificity reagents, methods for their preparation and use
WO2015197582A1 (fr) *	2014-06-27	2015-12-30	Innate Pharma	Protéines monomères multispécifiques de liaison aux antigènes
US10174095B2 (en) *	2014-07-21	2019-01-08	Novartis Ag	Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
KR102606190B1 (ko) *	2015-02-20	2023-11-23	오하이오 스테이트 이노베이션 파운데이션	Nkg2d 및 종양 연관 항원에 대해 유도된 이가 항체
PT3280432T (pt) *	2015-04-06	2021-04-22	Subdomain Llc	Polipéptidos que contêm domínio de ligação de novo e seus usos
WO2017165464A1 (fr) *	2016-03-21	2017-09-28	Elstar Therapeutics, Inc.	Molécules multispécifiques et multifonctionnelles et leurs utilisations
CA3221995C (fr) *	2017-02-08	2024-05-28	Dragonfly Therapeutics, Inc.	Proteines de fixation multi-specifiques destinees a l'activation de cellules tueuses naturelles et leurs utilisations therapeutiques pour traiter le cancer
US20200095327A1 (en) *	2017-02-08	2020-03-26	Dragonfly Therapeutics, Inc.	Antibody heavy chain variable domains targeting the nkg2d receptor
US20190375838A1 (en) *	2017-02-10	2019-12-12	Dragonfly Therapeutics, Inc.	Proteins binding bcma, nkg2d and cd16
US20200179511A1 (en) *	2017-04-28	2020-06-11	Novartis Ag	Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor

2018
- 2018-02-09 US US16/484,936 patent/US20190375838A1/en active Pending
- 2018-02-09 KR KR1020197026174A patent/KR20190115469A/ko not_active Ceased
- 2018-02-09 JP JP2019543761A patent/JP7257323B2/ja active Active
- 2018-02-09 BR BR112019016424A patent/BR112019016424A2/pt not_active Application Discontinuation
- 2018-02-09 SG SG11201907253VA patent/SG11201907253VA/en unknown
- 2018-02-09 KR KR1020247004861A patent/KR20240078657A/ko not_active Ceased
- 2018-02-09 MX MX2019009566A patent/MX2019009566A/es unknown
- 2018-02-09 CA CA3054642A patent/CA3054642A1/fr active Pending
- 2018-02-09 MA MA047465A patent/MA47465A/fr unknown
- 2018-02-09 CN CN201880021558.4A patent/CN110461361A/zh active Pending
- 2018-02-09 AU AU2018219348A patent/AU2018219348A1/en not_active Abandoned
- 2018-02-09 MY MYPI2019004552A patent/MY205850A/en unknown
- 2018-02-09 WO PCT/US2018/017653 patent/WO2018148566A1/fr not_active Ceased
- 2018-02-09 EP EP18750616.7A patent/EP3579876A4/fr active Pending
2019
- 2019-08-07 IL IL268567A patent/IL268567A/en unknown
2022
- 2022-12-08 JP JP2022196214A patent/JP2023029988A/ja active Pending

Also Published As

Publication number	Publication date
JP2020507328A (ja)	2020-03-12
MY205850A (en)	2024-11-15
RU2019127910A (ru)	2021-03-10
SG11201907253VA (en)	2019-09-27
RU2019127910A3 (fr)	2021-06-15
MX2019009566A (es)	2020-01-20
KR20240078657A (ko)	2024-06-04
IL268567A (en)	2019-09-26
JP7257323B2 (ja)	2023-04-13
JP2023029988A (ja)	2023-03-07
AU2018219348A1 (en)	2019-08-29
KR20190115469A (ko)	2019-10-11
BR112019016424A2 (pt)	2020-04-07
CN110461361A (zh)	2019-11-15
CA3054642A1 (fr)	2018-08-16
US20190375838A1 (en)	2019-12-12
WO2018148566A1 (fr)	2018-08-16
EP3579876A1 (fr)	2019-12-18
EP3579876A4 (fr)	2020-11-18

Publication	Publication Date	Title
MA47465A (fr)	2019-12-18	Protéines fixant le bcma, le nkg2d et le cd16
IL268755A (en)	2019-10-31	Proteins binding her2, nkg2d and cd16
IL272374A (en)	2020-03-31	Proteins binding nkg2d, cd16 and flt3
IL280512A (en)	2021-03-25	Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
IL281305A (en)	2021-04-29	Proteins that bind CD16, NKG2D, and CCR4, EGFR, or PD-L1
IL268790A (en)	2019-10-31	CD33, NKG2D and CD16 binding proteins
IL323220A (en)	2025-11-01	Engineered DNA-binding proteins
EP3630181A4 (fr)	2021-03-17	Protéine de liaison nkg2d, cd16 et antigène associé à une tumeur
IL270803A (en)	2020-01-30	A protein binding nkg2d, cd16 and a tumor-associated antigen
IL270794A (en)	2020-01-30	NKG2D binding protein, CD16 and ROR1 or ROR2
EP3679071A4 (fr)	2021-06-09	Protéines de liaison à nkg2d, cd16 et un antigène associé à une tumeur
IL268574A (en)	2019-09-26	proteins that bind psma, nkg2d, and cd16
IL268768A (en)	2019-10-31	Proteins binding gd2, nkg2d and cd16
IL268766A (en)	2019-10-31	Proteins that bind NKG2D, CD123, and CD16
DK3275895T3 (da)	2021-09-27	Neuropilin-1-specifikt bindingspeptid, fusionsprotein fusioneret dermed, og anvendelse deraf
IL273202A (en)	2020-04-30	Human thrombin receptor binding proteins, PAR4
HK40014030A (en)	2020-08-14	Proteins binding bcma, nkg2d and cd16
ZA201905273B (en)	2023-06-28	Proteins binding psma, nkg2d and cd16
HK40055054A (en)	2022-03-04	Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
ZA202001042B (en)	2021-05-26	Antibody specifically binding to pauf protein, and use thereof
HK40019178A (en)	2020-10-09	Proteins binding psma, nkg2d and cd16
HK40014039A (en)	2020-08-14	Proteins binding cd33, nkg2d and cd16
HK40030226A (en)	2021-02-26	Proteins binding nkg2d, cd16 and flt3
HK40040805A (en)	2021-08-06	Engineered dna binding proteins
HK40019734A (en)	2020-10-16	Proteins binding cd123, nkg2d and cd16